LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

LIGAND PHARMACEUTICALS INCORPORATED Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 42.70% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-07

• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-06-30 was 42.70%, a 0.93% decline year-over-year.
• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 42.30%, a 7.84% decline year-over-year.
• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-09-30 was 40.00%, a 10.51% decline year-over-year.
• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-06-30 was 43.10%, a 5.27% decline year-over-year.